C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 5.75 USD 3.6%
Market Cap: 77.1m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

CASI Pharmaceuticals Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CASI Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
CASI Pharmaceuticals Inc
NASDAQ:CASI
Total Liabilities & Equity
$75.3m
CAGR 3-Years
-16%
CAGR 5-Years
-8%
CAGR 10-Years
17%
Abbvie Inc
NYSE:ABBV
Total Liabilities & Equity
$143.4B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities & Equity
$54.5B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Liabilities & Equity
$90.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities & Equity
$22.2B
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities & Equity
$37.4B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
26%

See Also

What is CASI Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
75.3m USD

Based on the financial report for Dec 31, 2023, CASI Pharmaceuticals Inc's Total Liabilities & Equity amounts to 75.3m USD.

What is CASI Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
17%

Over the last year, the Total Liabilities & Equity growth was -22%. The average annual Total Liabilities & Equity growth rates for CASI Pharmaceuticals Inc have been -16% over the past three years , -8% over the past five years , and 17% over the past ten years .

Back to Top